AHA GUIDELINES Bundle (free trial)

Management of Adults With Congenital Heart Disease

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1541979

Contents of this Issue

Navigation

Page 27 of 93

28 Specific Conditions 4.1.1. Atrial Septal Defect COR LOE Recommendations Diagnostic 1 B-NR 1. In adults with an unrepaired ASD, CMR imaging, transesophageal echocardiography, or cardiac CT is recommended to define defect size, morpholog y, rim anatomy, and pulmonary venous connections. 1 B-NR 2. Adults with an unrepaired ASD and PAH should undergo risk assessment and management in consultation with pulmonary hypertension specialists to improve outcomes. 1 C-EO 3. Adults with an unrepaired ASD should be assessed for the presence of PAH to guide medical therapy and determine suitability for repair. 2b C-LD 4. In adults with an unrepaired ASD, balloon test occlusion before closure may be reasonable to assess hemodynamic changes. erapeutic 1 B-R 5. In adults with an unrepaired ASD, significant left-to-right shunt (Qp:Qs ≥ 1.5) and right ventricular (RV) dilation, in the absence of PAH (PVR ≤2 Wood units) or significant LV disease*, ASD closure is recommended to improve functional class and clinical outcomes. 1 B-NR 6. In adults with an isolated unrepaired secundum ASD, transcatheter closure is usually preferred to surgical repair to reduce length of stay and recovery time. 1 C-EO 7. In adults with an unrepaired ASD and evidence of (or strong suspicion for) paradoxical embolism, ASD closure is recommended to prevent recurrent embolism. 2a B-R 8. In adults with an unrepaired ASD, significant left-to-right shunt (Qp:Qs ≥1.5) and RV dilation, with a PVR >2 to <5 Wood units, and without significant LV disease,* ASD closure is reasonable to improve functional status. 2a B-NR 9. In adults with an unrepaired ASD, significant left-to-right shunt (Qp:Qs ≥1.5), RV dilation, PAH (PVR 5 to 8 Wood units), and without significant LV disease, closure can be beneficial if PVR <5 Wood units can be achieved with targeted PAH therapy, to improve medium-term functional status.

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Management of Adults With Congenital Heart Disease